A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib

Abstract The hematopoietic cell kinase (HCK) regulates BTK activation and represents a potential therapeutic target in Waldenstrom macroglobulinemia (WM). We investigated dasatinib, a potent HCK inhibitor, in patients with WM progressing on ibrutinib. Study treatment consisted of dasatinib administe...

Full description

Bibliographic Details
Published in:eJHaem
Main Authors: Jorge J. Castillo, Shayna Sarosiek, Catherine A. Flynn, Carly Leventoff, Megan Little, Timothy White, Kirsten Meid, Steven P. Treon
Format: Article
Language:English
Published: Wiley 2022-08-01
Subjects:
clinical trial
dasatinib
HCK
Waldenström macroglobulinemia
Online Access:https://doi.org/10.1002/jha2.493

Internet

https://doi.org/10.1002/jha2.493

Similar Items